Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Advicenne Appoints Ludovic Robin as Chief Business & Strategy Officer

Posted on: 01 Sep 16

Advicenne a French pharmaceutical laboratory dedicated to pediatric and orphan diseases announces the nomination of Ludovic Robin as Chief Business & Strategy Officer.

This Smart News Release features multimedia. View the full release here:

Advicenne Appoints Ludovic Robin as Chief Business & Strategy Officer (Photo: Business Wire)

Ludovic Robin joins Advicenne to lead Global commercial and corporate development focusing on the main Business areas, both in the US and EU.

He brings over 25 years of international R&D, Marketing& Sales and Business development experiences in the Pharmaceutical industry. During his career, Ludovic launched more than 15 new original products for rare diseases or for highly specialized medicines.

He started his career in the United Kingdom as scientist developing new cosmetology and dermatological formulations for Procter & Gamble and Stiefel laboratories. Then he came back to France where he led various managerial and leadership roles in sales, marketing and business Development within L’Oréal, Servier and Laboratoires Expanscience. During this period, he originated, signed and executed 13 partnerships (registration, commercial) in more than 20 countries.

In 2004, he joined Shire to launch the dermatology and the nephrology franchises. He served as marketing manager, Business unit Director, Marketing Director and Commercial Operation Head for France and BeNeLux , concerning in particular nephrology and child psychiatry. He was a member of Shire French Executive board since 2008.

Ludovic Robin received his Doctorate in Pharmacy (PharmD) and his Master in Industrial Pharmacy from Lyon I University and completed his MBA at HEC Paris (and Mc Gill- Montreal).

About Advicenne,

Advicenne, a fast-growing specialty pharma, focuses on innovative pediatric medications, targeting orphan or neglected diseases within the fields of neurology and nephrology and aims to become a world leader in those therapeutic areas.
The company has today a strong portfolio of products in late-stage development targeting critical unmet needs in nephrology and epilepsy, and has started its commercial activities late 2015 with its first product on the French market.

View source version on

Business Wire

Last updated on: 01/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.